Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?

Genetic differences between individuals have been predicted to account for disparate outcomes in patients diagnosed with cancer. The search for genetic determinants has been ongoing for a considerable amount of time and it is only now that insights have been gained into which polymorphisms are most...

Descripción completa

Detalles Bibliográficos
Autor principal: Scott, Rodney J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880429/
https://www.ncbi.nlm.nih.gov/pubmed/20156327
http://dx.doi.org/10.1186/bcr2474
_version_ 1782182029160349696
author Scott, Rodney J
author_facet Scott, Rodney J
author_sort Scott, Rodney J
collection PubMed
description Genetic differences between individuals have been predicted to account for disparate outcomes in patients diagnosed with cancer. The search for genetic determinants has been ongoing for a considerable amount of time and it is only now that insights have been gained into which polymorphisms are most likely to be important in determining not only disease likelihood but also outcome. The quest to be able to accurately predict patient outcomes in breast cancer may now be a step closer as increased sample size is leading to more robust statistical analysis and a better understanding of molecular mechanisms of disease are forthcoming.
format Text
id pubmed-2880429
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28804292010-08-03 Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer? Scott, Rodney J Breast Cancer Res Editorial Genetic differences between individuals have been predicted to account for disparate outcomes in patients diagnosed with cancer. The search for genetic determinants has been ongoing for a considerable amount of time and it is only now that insights have been gained into which polymorphisms are most likely to be important in determining not only disease likelihood but also outcome. The quest to be able to accurately predict patient outcomes in breast cancer may now be a step closer as increased sample size is leading to more robust statistical analysis and a better understanding of molecular mechanisms of disease are forthcoming. BioMed Central 2010 2010-02-03 /pmc/articles/PMC2880429/ /pubmed/20156327 http://dx.doi.org/10.1186/bcr2474 Text en Copyright ©2010 BioMed Central Ltd
spellingShingle Editorial
Scott, Rodney J
Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?
title Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?
title_full Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?
title_fullStr Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?
title_full_unstemmed Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?
title_short Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?
title_sort have the roles of two functional polymorphisms in breast cancer, r72p in p53 and mdm2-309 in mdm2, become clearer?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880429/
https://www.ncbi.nlm.nih.gov/pubmed/20156327
http://dx.doi.org/10.1186/bcr2474
work_keys_str_mv AT scottrodneyj havetherolesoftwofunctionalpolymorphismsinbreastcancerr72pinp53andmdm2309inmdm2becomeclearer

Ejemplares similares